龙8-long8_龙8-long8(国际)唯一官方网站

·Past General Manager, Chengdu ChemPartner Co. Ltd., China
·Past Vice President of Medicinal Chemistry, Shanghai ChemPartner Co. Ltd., China
·Past Chief Scientific Officer, Egret Pharma (Shanghai) Ltd, Shanghai, China
·Past Senior Scientist II and project leader, Bayer Healthcare, Pharmaceutical Product Division, USA
·Past Senior Research Scientist, AbbVie, Abbott Park, Pharmaceutical Product Division, USA
·Inventor and co-inventor of more than 20 compounds that are in Phase I, II and III clinical trials (influenza neuraminidase inhibitor, VEGFR inhibitor, SGLT2 inhibitor, AR inhibitor)

·Past Senior Director, Shanghai ChemPartner Co. Ltd., China
·Past Director, AstraZeneca Pharmaceutical Co. Ltd. China
·Past Senior Scientist, Merck & Co, USA
·Inventor and co-inventor of 6 compounds that are in Phase I, II and III clinical trials (Glargine, AMPK agonist, Smart Insulin, TrpC6 inhibitor, NPT2 inhibitor, AR inhibitors et al.)
·Key contributor of approved long-acting insulin Lusduna Nexvue for diabetes treatment

·Past Deputy Manager, Sihai Tongxing Holding Co. Ltd., Chengdu Wintrue Holding Co.Ltd., China
·Past President of Sichuan Tongtai Zhongying Investment Management Co. Ltd., China
·Past HR Supervisor, Chengdu Wintrue Holding Co.Ltd., China
·Ms. Dai has over 10-year experience in company operation and management. She has led investment and financing projects covering RMB 2 billion in healthcare and pharmaceutical industry.

·Mr. Tang has over 20 years of commercial experience in global pharmaceutical and biotech companies
·Served in AstraZeneca, Pfizer, Roche, BMS and other global pharmaceutical companies
·Prior to joining Hinova, Mr. Tang served as Vice President at RemeGen, with responsibilities of product commercialization and marketing. Under the leadership of Mr. Tang, the first Chinese ADC drug (Disitamab Vedotin) launched successfully and was included in the National Reimbursement Drug List (NRDL).

·Served in Zhongshan Liyuan Decoration Engineering Ltd., Zhongshan Fuyi Construction Ltd. and Zhongshan Yingyi Engineering Consultants Ltd., China
·Mr. Chen has over 20-years experience of engineering and construction. Before joining Hinova, he played key roles in many construction projects with an average value more than 1 billion.

·Past Senior Scientist, PTC Therapeutics, Inc., USA
·Past Senior Research Chemist, Merck & Co, USA
·Inventor and co-inventor of more than 10 compounds that are in Phase I, II and III clinical trials (SSTR3 Inhibitor, RG7800, et al.)

·Past Director, Shanghai ChemPartner Co. Ltd., China
·Past Senior Director, Chengdu ChemPartner Co. Ltd., China
·Inventor and involved in development of more than 10 compounds that are in Phase I, II, III clinical trials or commercial products

·Past Project Leader, Shanghai ChemPartner Co. Ltd., China
·Past Group Leader, Chengdu ChemPartner Co. Ltd., China
·Past Scientist, Zhejiang Hisun Pharmaceutical CO., LTD., China
·Managed CMC of multiple compounds that are in IND, and Phase I, II and III clinical trials (HC-1119 et al.)

·Past Chief Business Officer, Eutilex Co. Ltd.，Korea/USA
·Past Chief Business Officer, 1ST Biotherapeutics, Inc., USA
·Past Head of Business, Innate Pharma, S.A., France
·Past Director of Business, Micromet AG, Germany
·Over 20 years of experience in pharmaceutical industry strategy and business financing, several IPOs, M&A, proficient in business and negotiation strategies